Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
NURIX THERAPEUTICS, INC.
nurixtx.comAI Executive Summary
AI-powered analysis of 8-K filing content
Nurix Therapeutics entered into an exclusive worldwide license and collaboration agreement with Roche and Genentech for bexobrutideg (NX-5948), a BTK-targeting small molecule. This partnership validates Nurix's technology platform and provides significant development and commercialization resources from a major pharmaceutical company.
Key Takeaways
Roche gains exclusive worldwide rights to develop, manufacture, and commercialize bexobrutideg (NX-5948), a Bruton's tyrosine kinase inhibitor
Agreement leverages Nurix's intellectual property and represents validation of the company's drug discovery platform by a tier-one pharma partner
2 more takeaways